Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06679959 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ASC30 Injection in Participants With Obesity
A Phase 1 study of Chronic Weight Management, sponsored by Ascletis Pharma (China) Co., Limited.
- Active
- Registry status
- Phase 1
- Development phase
- 115
- Enrollment target
- 1
- Study location
NCT06679959 is a Phase 1 study of Chronic Weight Management that is active but no longer recruiting, run by Ascletis Pharma (China) Co., Limited. The registered enrollment target is 115 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06679959, a Phase 1 study of Chronic Weight Management, is active but no longer recruiting, sponsored by Ascletis Pharma (China) Co., Limited.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 115 participants
- Enrollment target
- 1
- Study location
Study Summary
This randomized, double-blind, placebo-controlled single ascending dose (SAD)/ multiple ascending dose (MAD) study is designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ASC30 injection
Conditions Studied
Interventions
- DRUG ASC30 Injection, for subcutaneous use or placebo
Study Locations (1)
Texas
- Ascletis clinical site - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2024-09-16 |
| Est. Completion | 2026-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06679959
The ClinicalTrials.gov registry entry for NCT06679959 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 115 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ascletis Pharma (China) Co., Limited, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Weight Management appearing as the primary indexed condition, and to 1 intervention - of which ASC30 Injection, for subcutaneous use or placebo is the first listed.
NCT06679959 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06679959 about?
NCT06679959 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ASC30 Injection in Participants With Obesity". This randomized, double-blind, placebo-controlled single ascending dose (SAD)/ multiple ascending dose (MAD) study is designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ASC30 injection
What is the current status of trial NCT06679959?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 115 participants. The study started on 2024-09-16. Estimated completion is 2026-04.
What conditions does trial NCT06679959 study?
This clinical trial studies the following conditions: Chronic Weight Management.
What interventions are being tested in trial NCT06679959?
The interventions under investigation include: ASC30 Injection, for subcutaneous use or placebo (DRUG).
Who is sponsoring clinical trial NCT06679959?
This trial is sponsored by Ascletis Pharma (China) Co., Limited, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06679959 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Weight Management
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Combination With Semaglutide
COMPLETED · Phase 1
-
A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.